Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-26 · accession 0000875320-25-000135 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-28 | 2025-02-26 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $479.61 | -4,962 | 59.1K | -8% | -$2.38M | |
| 2025-02-28 | 2025-02-27 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $475.34 | -530 | 58.5K | -0.9% | -$251.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | F | D | 4,962 | $479.61 | 59,069 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-27 | S | D | 530 | $475.34 | 58,539 | D | — | — |